Jean-Jacques VOISARD
Pierre Fabre
Jean-Jacques VOISARD is Global Head of Medical Dermatology Franchise at Pierre Fabre, operating in 80 countries. Medical Dermatology is one of the 3 Global Pharma Franchises of Pierre Fabre Group, a 3,1 B€ French pharma company, known for its expertise in dermatology, dermo-cosmetics and oncology.
Since he joined the Franchise in Nov.2003, and before being appointed Global Head in 2013, Jean-Jacques has held several positions in the Franchise (Head of Medical Affairs, Head of Marketing/Development, Head of the French Subsidary where PF lead the market in terms of drug prescriptions by dermatologists).
Jean-Jacques has led the worldwide development of the first and only oral solution of beta-blocker specifically designed for safe and effective use in infants with Infantile Hemangiomas requiring systemic therapy. The development included an innovative phase II/III clinical trial, with results published in New England Journal of Medicine in 2015 . It is currently approved in 34 countries (EU, USA, Switzerland, Canada, Mexico, Russia, Japan...). Hemangiol was awarded “ Drug of the year in 2014 in France” by the Prix Galien.
Prior to joining Pierre Fabre, Jean-Jacques was General Manager for Aster Dermatologie, a french CRO fully dedicated to the clinical evaluation of dermo-cosmetic products and drugs in dermatology, where he had the opportunity to conduct clinical trials for major companies in dermatology.
Jean-Jacques is a board certified dermatologist and was trained in Bordeaux (France).
Since he joined the Franchise in Nov.2003, and before being appointed Global Head in 2013, Jean-Jacques has held several positions in the Franchise (Head of Medical Affairs, Head of Marketing/Development, Head of the French Subsidary where PF lead the market in terms of drug prescriptions by dermatologists).
Jean-Jacques has led the worldwide development of the first and only oral solution of beta-blocker specifically designed for safe and effective use in infants with Infantile Hemangiomas requiring systemic therapy. The development included an innovative phase II/III clinical trial, with results published in New England Journal of Medicine in 2015 . It is currently approved in 34 countries (EU, USA, Switzerland, Canada, Mexico, Russia, Japan...). Hemangiol was awarded “ Drug of the year in 2014 in France” by the Prix Galien.
Prior to joining Pierre Fabre, Jean-Jacques was General Manager for Aster Dermatologie, a french CRO fully dedicated to the clinical evaluation of dermo-cosmetic products and drugs in dermatology, where he had the opportunity to conduct clinical trials for major companies in dermatology.
Jean-Jacques is a board certified dermatologist and was trained in Bordeaux (France).